Effective date: 8/5/2019

    The formulary of topical ocular pharmaceutical agents consists of pharmaceutical agents that are appropriate to treat or diagnose ocular disease and disorders and which a certified optometrist is qualified to administer and prescribe in the practice of optometry pursuant to section 463.0055(2)(a), F.S. The topical ocular pharmaceutical agents in the formulary include the following legend drugs alone or in combination in concentrations up to those specified, or any lesser concentration:
    (1) CYCLOPLEGIC AND MYDRIATICS
    (a) Atropine sulfate — 1.0% (solution and ointment);
    (b) Phenylepherine HCl — 2.5%;
    (c) Cyclopentolate HCl — 0.5%, 1.0%;
    (d) Scopolamine HBr — 0.25%;
    (e) Homatropine HBr — 2.0%, 5.0%;
    (f) Tropicamide — 0.5%, 1.0%; and,
    (g) Hydroxyamphetamine HBr — 1.0% plus tropicamide — 0.25%.
    (2) LOCAL ANESTHETICS
    (a) Tetracaine — 0.5%;
    (b) Proparacaine HCl — 0.5%; and,
    (c) Benoxinate HCl — 0.4% (in combination with fluorescein).
    (3) DIAGNOSTIC PRODUCTS
Fluorescein paper strips — 1 mg, 9 mg per strip.
    (4) ANTIBACTERIAL
    (a) Erythromycin — 0.5%;
    (b) Bacitracin — 400 units/g, 500 units/g (ointment alone and in combination);
    (c) Polymyxin — 10,000 units/g (only in combination);
    (d) Neomycin — 1.75 mg/g, 1.75 mg/ml, 3.50 mg/g (only in combination);
    (e) Gentamicin — 0.3% (solution and ointment);
    (f) Tobramycin — 0.3% (solution and ointment in combination);
    (g) Gramicidin — 0.025 mg/ml (only in combination);
    (h) Ciprofloxacin HCl — 0.3% (solution and ointment);
    (i) Trimethoprim — 1.0 mg/ml (only in combination);
    (j) Ofloxaxin — 0.3%;
    (k) Levofloxacin — 1.5%;
    (l) Gatifloxacin — 0.5%;
    (m) Moxifloxacin — 0.5%;
    (n) Sodium sulfacetamide — 10.0% (alone and in combination);
    (o) Azithromycin — 1%; and,
    (p) Besifloxacin Ophthalmic Suspension — 0.6%.
    (5) NON-STEROIDAL AND STEROIDAL ANTI-INFLAMMATORY AGENTS
    (a) Medrysone — 1.0%;
    (b) Prednisolone acetate — 0.12%, 0.125%, 0.2%, 0.5%, 0.6%, 1.0% (alone and in combination);
    (c) Prednisolone sodium phosphate — 0.125%, 0.25%, 1.0% (alone and in combination);
    (d) Flurometholone — 0.1%, 0.25% (suspension and ointment, alone and in combination);
    (e) Dexamethasone — 0.1%, 1.0% (alone and in combination);
    (f) Dexamethasone sodium phosphate — 0.1% (solution and ointment);
    (g) Fluorometholone acetate — 0.1%;
    (h) Rimexolone — 1.0%;
    (i) Loteprednol etabonate — 0.2%, 0.5% (alone and in combination);
    (j) Diclofenac sodium — 0.1%;
    (k) Ketorolac tromethamine — 0.5%;
    (l) Hydrocortisone — 1.0% (only in combination);
    (m) Bromfenac — .09%;
    (n) Nepafenac — 0.1%; and,
    (o) Difluprednate opthalmic emulsion — .05%
    (p) Loteprednol etabonate ophthalmic suspension — 1%.
    (6) ANTIHISTAMINES, MAST CELL STABILIZERS AND ANTI-ALLERGY AGENTS
    (a) Cromolyn sodium — 4.0%;
    (b) Lodoxamide tromethamine — 0.1%;
    (c) Olopatadine HCl — 0.7%;
    (d) Nedocromil sodium — 2.0%;
    (e) Azelastine HCl — 0.05%:
    (f) Pemirolast potassium — 0.1%;
    (g) Epinastine HCl — 0.05%;
    (h) Bepotastine besilate — 1.5%; and,
    (i) Alcaftadine — .25%.
    (7) ANTIVIRAL AGENTS
    (a) Trifluridine — 1.0%;
    (b) Ganciclovir — 0.15%; and,
    (c) Povidone-iodine ophthalmic solution 5%.
    (8) ANTI-GLAUCOMA AGENTS
    (a) Beta Blockers.
    1. Betaxolol HCl — 0.25%, 0.5%;
    2. Levobunolol HCl — 0.25%, 0.5%;
    3. Metipranolol HCl — 0.3%;
    4. Timolol maleate or hemihydrate — 0.25%, 0.5% (solution and gel, alone and in combination); and,
    5. Carteolol HCl — 1.0%.
    (b) Miotics, Direct-acting
    1. Carbachol — 0.75%, 1.5%, 3.0%;
    2. Pilocarpine HCl — 0.5%, 1.0%, 2.0%, 4.0%; and,
    3. Pilocarpine gel — 4.0%.
    (c) Prostaglandins
    1. Latanoprost — 0.005%;
    2. Bimatoprost — 0.03%;
    3. Travoprost — 0.004%;
    4. Tafluprost — 0.0015%;
    5. Unoprostone Isoprophyl — 0.15%; and,
    6. Latanoprostene Bunod Ophthalmic Solution — 0.024%.
    (d) Alpha2 Adrenergic Agonist
    1. Brimonidine tartrate — 0.15%, 0.2%; and,
    2. Apraclonidine HCl — 0.5%.
    (e) Carbonic Anhydrase Inhibitors (CAI’s)
    1. Brinzolamide — 1.0%; and,
    2. Dorzolamide HCl — 2.0% (alone and in combination).
    (f) Rho Kinase Inhibitor — Netarsudil — 0.02%;
    (9) MISCELLANEOUS
    (a) Hydroxypropyl cellulose ophthalmic Insert;
    (b) Dapiprazole — 0.5%;
    (c) Cyclosporine emulsion — 0.05%;
    (d) Polyvinyl pyrrolidone — drops 2.0%;
    (e) Bimatoprost — .03%;
    (f) Natamycin Opthalmic Suspension 5%;
    (g) Lifitegrast ophthalmic solution 5%; and,
    (h) Cyclosporine 0.09% Opthalmic Solution.
Rulemaking Authority 463.005, 463.0055(2)(a) FS. Implements Florida Statutes § 463.0055. History—New 3-30-87, Amended 4-5-88, 5-7-90, Formerly 21-18.002, Amended 5-10-92, 1-29-93, Formerly 21Q-18.002, Amended 8-31-93, 7-30-94, Formerly 61F8-18.002, Amended 2-11-96, 4-21-96, 1-12-97, 6-8-97, Formerly 59V-18.002, Amended 6-15-00, 6-7-05, 6-10-06, 6-26-08, 10-16-08, 3-23-09, 6-28-09, 10-18-09, 4-21-10, 12-26-10, 7-21-11, 11-11-12, 11-29-13, 12-9-13, 4-10-14, 8-14-15, 1-20-17, 8-31-18, 1-25-19, 8-5-19.